About this data
Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.
Lixisenatide
- Company
- Sanofi
- Mechanism
- Mechanism not yet reported
- Route
- Route not yet reported
- Recruiting trials
- 2 recruiting
Efficacy results: Not yet reported
2 recruiting studies currently listed on ClinicalTrials.gov.
Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026
Find a Clinical Trial Near Me
See recruiting studies for Lixisenatide and check eligibility with the study team.
Trial details
-
Recruiting NCT NCT06671587
iGlarLixi CGM Study in Chinese T2D Individuals After OADs
Not yet reported Sanofi 678 participants Est. completion 2026-09-18 1 site Stand-aloneType 2 diabetesView official trial listing → -
Recruiting NCT NCT07307235
Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents
Not yet reported Shanghai Zhongshan Hospital 1316 participants Est. completion 2027-12-30 24 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT00299871
Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus
Not yet reported Sanofi 542 participants Est. completion 2007-08 7 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT00688701
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy
Not yet reported Sanofi 361 participants Est. completion 2009-12 12 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT00707031
GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
Not yet reported Sanofi 639 participants Est. completion 2010-11 18 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT00712673
GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
Not yet reported Sanofi 680 participants Est. completion 2011-03 16 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT00713830
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea
Not yet reported Sanofi 859 participants Est. completion 2011-01 16 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT00715624
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin
Not yet reported Sanofi 496 participants Est. completion 2011-02 15 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT00763451
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
Not yet reported Sanofi 484 participants Est. completion 2011-01 15 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT00763815
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone
Not yet reported Sanofi 484 participants Est. completion 2011-06 150 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT00866658
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)
Not yet reported Sanofi 311 participants Est. completion 2010-06 4 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT00905255
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS)
Not yet reported Sanofi 69 participants Est. completion 2011-01 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT00931372
Lixisenatide for Restoration of Insulin Release in Subjects With Diabetes Mellitus Type 2
Not yet reported Sanofi 22 participants Est. completion 2009-08 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT00975286
24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
Not yet reported Sanofi 446 participants Est. completion 2011-08 140 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT00976937
24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
Not yet reported Sanofi 319 participants Est. completion 2011-03 92 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT01146678
Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1
Not yet reported Sanofi 22 participants Est. completion 2011-01 1 site Stand-aloneOther conditions: Type 1 Diabetes MellitusView official trial listing → -
Completed NCT NCT01147250
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)
Not yet reported Sanofi 6068 participants Est. completion 2015-02 829 sites Stand-aloneOther conditions: Acute Coronary SyndromeView official trial listing → -
Completed NCT NCT01169779
Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin
Not yet reported Sanofi 391 participants Est. completion 2011-12 35 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT01175473
Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes
Not yet reported Sanofi 148 participants Est. completion 2010-11 7 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT01476475
Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients
Not yet reported Sanofi 323 participants Est. completion 2012-12 70 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT01517412
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
Not yet reported Sanofi 451 participants Est. completion 2013-05 82 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT01572649
Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes
Not yet reported Sanofi 24 participants Est. completion 2014-03 6 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT01596504
Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin
Not yet reported Sanofi 142 participants Est. completion 2013-07 8 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT01632163
Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin
Not yet reported Sanofi 447 participants Est. completion 2015-05 51 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT01768559
Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients
Not yet reported Sanofi 894 participants Est. completion 2014-12 199 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT01798706
Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients
Not yet reported Sanofi 350 participants Est. completion 2015-02 83 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT01910194
Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying
Not yet reported Profil Institut für Stoffwechselforschung GmbH 39 participants Est. completion 2014-10 2 sitesOther conditions: Diabetes MellitusView official trial listing → -
Completed NCT NCT01940965
Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes
Not yet reported Sanofi 294 participants Est. completion 2015-07 27 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT01960179
Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes
Not yet reported Sanofi 361 participants Est. completion 2015-03 30 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT01973231
Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes
Not yet reported Novo Nordisk A/S 404 participants Est. completion 2014-11 61 sitesType 2 diabetes Other conditions: DiabetesView official trial listing → -
Completed NCT NCT02020629
Study on Lixisenatide and Counterregulation to Hypoglycemia
Not yet reported Lund University 18 participants Est. completion 2015-08 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT02049034
Lixisenatide-The Effects on Glucose and Lipid Metabolism in Type 2 Diabetes
Not yet reported University of Surrey 8 participants Est. completion 2016-01 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT02058147
Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM
Not yet reported Sanofi 1170 participants Est. completion 2015-06 273 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT02058160
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes
Not yet reported Sanofi 736 participants Est. completion 2015-07 236 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT02168491
Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin
Not yet reported Medical University of Vienna 10 participants Est. completion 2015-08 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT02200991
Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine
Not yet reported Sanofi 136 participants Est. completion 2015-11 20 sites Stand-aloneType 2 diabetesView official trial listing → -
Terminated NCT NCT02231658
Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion
Not yet reported Profil Institut für Stoffwechselforschung GmbH 109 participants Est. completion 2018-07-23 2 sites Stand-aloneOther conditions: Diabetes MellitusView official trial listing → -
Terminated NCT NCT02244164
Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.
Not yet reported Erasme University Hospital 5 participants Est. completion 2023-02-13 1 siteType 2 diabetes Other conditions: Incretinomimetics, PancreasView official trial listing → -
Terminated NCT NCT02274740
Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients
Not yet reported Sanofi 2 participants Est. completion 2015-08 Stand-aloneOther conditions: Type II Diabetes MellitusView official trial listing → -
Completed NCT NCT02276196
Effect of LIXIsenatide on the Renal System
Not yet reported Amsterdam UMC, location VUmc 40 participants Est. completion 2016-04 1 site Stand-aloneChronic kidney disease Other conditions: Diabetes Mellitus, Glucagon-Like Peptide 1View official trial listing → -
Status unknown NCT NCT02308254
Drug Trial of Lixisenatide on Gastric Emptying and Blood Pressure Drops in Type 2 Diabetics and Healthy People
Not yet reported, Not yet reported Royal Adelaide Hospital 30 participants Est. completion 2016-04 1 siteOther conditions: Diabetes Mellitus, GastroparesisView official trial listing → -
Status unknown NCT NCT02501850
The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)
Not yet reported Hospital Universitari Vall d'Hebron Research Institute 40 participants Est. completion 2015-10 1 site Added to GLP-1Type 2 diabetesView official trial listing → -
Completed NCT NCT02640118
The Impact of Lixisenatide on Postprandial Glucose Tolerance in Pancreatectomised Subjects
Not yet reported University Hospital, Gentofte, Copenhagen 24 participants Est. completion 2016-07Other conditions: Diabetes After Total PancreatectomyView official trial listing → -
Completed NCT NCT02713477
Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus
Not yet reported Sanofi 20 participants Est. completion 2016-06 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT02745470
Effects of a GLP-1 Receptor Agonist on Functional Activation and Connectivity of the Brain
Not yet reported Seoul National University Hospital 30 participants Est. completion 2016-12 1 site Stand-aloneOther conditions: Diabetes MellitusView official trial listing → -
Completed NCT NCT02749890
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
Not yet reported Sanofi 321 participants Est. completion 2018-05 61 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT02752412
Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs
Not yet reported Sanofi 513 participants Est. completion 2018-10-04 122 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT02752828
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
Not yet reported Sanofi 521 participants Est. completion 2018-03-12 113 sites Stand-aloneType 2 diabetesView official trial listing → -
Terminated NCT NCT02767596
Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog
Not yet reported Laniado Hospital 2 participants Est. completion 2017-02-21 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT02787551
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
Not yet reported Sanofi 514 participants Est. completion 2018-11-17 124 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT02803918
A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)
Not yet reported Sanofi 23 participants Est. completion 2020-01-27 11 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT02941367
Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan
Not yet reported Sanofi 184 participants Est. completion 2017-08-04 16 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT03130426
Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi
Not yet reported Population Health Research Institute 161 participants Est. completion 2020-09-30 8 sitesType 2 diabetesView official trial listing → -
Terminated NCT NCT03434119
Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents
Not yet reported Sanofi 241 participants Est. completion 2019-01-07 85 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT03439943
Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease
Not yet reported University Hospital, Toulouse 156 participants Est. completion 2021-04-15 20 sites Stand-aloneOther conditions: Parkinson DiseaseView official trial listing → -
Completed NCT NCT03492580
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
Janssen Research & Development, LLC 714582 participants Est. completion 2018-06-25 1 siteType 2 diabetesCardiovascular diseaseView official trial listing → -
Completed NCT NCT03529123
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)
Not yet reported Sanofi 247 participants Est. completion 2019-11-25 13 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT03767543
Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)
Not yet reported Sanofi 265 participants Est. completion 2020-10-23 32 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT03798054
Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)
Not yet reported Sanofi 878 participants Est. completion 2021-03-01 79 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT03798080
Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin
Not yet reported Sanofi 426 participants Est. completion 2020-12-01 45 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT03819790
The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians
Not yet reported LMC Diabetes & Endocrinology Ltd. 119 participants Est. completion 2019-11-19 3 sites Stand-aloneType 2 diabetesView official trial listing → -
Terminated NCT NCT03881995
Effects of Insulin Glargine and Lixisenatide on the Brain
Not yet reported University Hospital Tuebingen 1 participants Est. completion 2020-06-29 1 siteType 2 diabetesView official trial listing → -
Status unknown NCT NCT03959865
GLP-1 REceptor Agonists and Real World EvIdeNce
University of Padova 6000 participants Est. completion 2019-05-31 6 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT04184947
Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists
University of Padova 10000 participants Est. completion 2020-02-29 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT04196231
Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)
Not yet reported University of Campania Luigi Vanvitelli 258 participants Est. completion 2020-10-20 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT05114590
Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus
Not yet reported Sanofi 124 participants Est. completion 2023-04-14 18 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT05136287
SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY.
Jose Seijas Amigo 140 participants Est. completion 2024-01-01 11 sitesType 2 diabetes Other conditions: Weight Loss, Quality of Life, Safety IssuesView official trial listing → -
Active, not recruiting NCT NCT05220917
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
Brigham and Women's Hospital 781430 participants Est. completion 2027-09-30 1 siteType 2 diabetes Other conditions: Cardiovascular Events, Renal DiseaseView official trial listing → -
Completed NCT NCT05413369
iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)
Not yet reported Sanofi 582 participants Est. completion 2023-10-20 60 sites Stand-aloneType 2 diabetesView official trial listing → -
Status unknown NCT NCT05804513
The Effect of Lixisenatide on the Effect of Pituitary Hormones
Not yet reported University of Tartu 10 participants Est. completion 2023-12-31 1 siteOther conditions: Healthy, Type 1 DiabetesView official trial listing → -
Status unknown NCT NCT06449235
Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh
Not yet reported Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders 938 participants Est. completion 2025-06 1 siteOther conditions: Type2diabetesView official trial listing → -
Completed NCT NCT06716424
A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus
Not yet reported Sanofi 105 participants Est. completion 2026-06-12 10 sites Stand-aloneType 2 diabetesView official trial listing → -
Enrolling by invitation NCT NCT07117240
Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced Diabetes
Not yet reported Medical University of Warsaw 100 participants Est. completion 2028-07-10 1 site Stand-aloneOther conditions: Steroid-Induced Diabetes, Steroid-Induced Hyperglycemia, DiabetesView official trial listing → -
Not yet recruiting NCT NCT07173712
Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes
Not yet reported Yanbing Li 324 participants Est. completion 2027-12-31Type 2 diabetesView official trial listing → -
Active, not recruiting NCT NCT07188545
Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)
Ohio State University 23280000 participants Est. completion 2029-06-30 1 siteMetabolic syndromeView official trial listing →
Efficacy history
Not yet reported.
Safety
Not yet reported.
Sources
Also known as: Lixisenatide, Lixisenatide (AVE0010)
Related On The Pen coverage
No related coverage yet.
This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.